Prophylaxis of cardiovascular diseases in rheumatoid arthritis

Full Text

Abstract

One of the key causes of lethality in rheumatoid arthritis (RA) are cardiovascular catastrophes (myocardial infarction, stroke, sudden cardiac death) resultant from early development and rapid progression of atherosclerotic vascular lesion. The article presents current approaches to prevention of cardiovascular diseases in RA including assessment of overall cardiovascular risk for design of optimal strategy of correction of modification factors increasing probability of cardiovascular complications, strong control over inflammation and adequate use of drugs which may be harmful (glucocorticosteroids, nonsteroid anti-inflammatory drugs). Much attention is paid to perspectives of ACE inhibitors, angiotensin II receptor blockers, statins, TNFalpha inhibitors in prevention of cardiovaskular complicatoin in RA

References

  1. Naz S. M., Symmons D. F. Mortality in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007; 21: 871-883.
  2. Leuven S. I., Franssen R., Kastelein J. J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47: 3-7.
  3. Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80-85.
  4. Hansson G. K. Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 2005; 352: l685-1695.
  5. Goodson N. I., Willes N. J., Lunt N. C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arhtr. & Rheum. 2002; 46; 2010-2019.
  6. Haque S., Mirjafari H., Bruce I. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr. Opin. Lipidol. 2008; 19: 338-343.
  7. Aubry M.-C., Maradit-Kpemers H., Reinalda M. C. et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J. Rheumatol. 2007; 34: 937-942.
  8. Насонов Е. Л. Проблема атеротромбоза в ревматологии. Вестн. РАМН 2003; 7: 6-10.
  9. Peterson M. J., Symmons D. P., McCarrey D. W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - EULAR TASK FORCE "Cardiovascular risk management in RA". Ann. Rheum. Dis. 2008; 67 (suppl. II): 310.
  10. Giles J. T., Post W., Blumenthal R. S. et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2006; 6: 320-329.
  11. Oганов Р. Г., Погосова Г. В. Современные стратегии профилактики и лечения сердечно-сосудистых заболеваний. Кардиология 2007; 12: 4-9.
  12. Беленкова Ю. Н., Оганов Р. Г. (ред.) Кардиология: национальное руководство. М.: Гэотар-Медиа; 2007.
  13. Hall F. C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin. Rheumatology 2005; 44: 1473-1482.
  14. Scoldstem L., Hagfors L., Johannson J. et al. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 208-214.
  15. Naranjo A., Sokka T., Descalzo M. A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr. Res. Ther. 2008; 10: R30.
  16. Kremers H. M., Nicola P. J., Crowson C. S. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthr. & Rheum. 2004; 50(11): 3450-3457.
  17. Turesson C. et al. Cardiovascular risk factor, fitness and physical activity in rheumatic disease. Curr. Opin. Rheumatol. 2007; 19: 190-197.
  18. Metsios G. S., Stavropoulos-Kalinoglou A., Veldhuijzen J. J. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 2007; 47(3): 239-248.
  19. Клинические рекомендации европейского общества кардиологов - 2007 г. М.; 2008.
  20. Мартынов А. И., Шаркова Н. Е., Обухов А. А. Изменение упругоэластичных свойств периферических сосудов и параметров функции эндотелия на фоне применения комбинированного препарата периндоприл плюс индапамид у больных гипертонической болезнью. Кардиология 2008; 4: 25-28.
  21. Fliser D., Buchholz K., Haller H. et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
  22. Насонов Е. Л., Насонова В. А. (ред.) Ревматология: Национальное руководство. М.: Гэотар-Медиа; 2008.
  23. Flammer A. J., Sudano I., Hermann F. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008; 117: 2262-2269.
  24. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией, остеоартозом и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Новости доказательной медицины. www.OSSN.ru
  25. Каратеев А. Е. Использование целекоксиба в ревматологии, кардиологии и онкологии. Рус. мед. журн. 2007; 22: 1160-1168.
  26. Gazi I. F., Boumpas D. T., Mikhailidis D. P. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin. Exp. Rheumatol. 2007; 25: 102-111.
  27. Насонов Е. Л. Перспективы применения статинов в ревматологии. Рус. мед. журн. 2003; 11(23): 1273-1276.
  28. Abeles A. M., Pillinger M. Statins as antiinflammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthr. Rheum. 2006; 54: 393-407.
  29. Paraskevas K. I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin. Rheumatol. 2008; 27(3): 281-287.
  30. Sarantopoulos A. A., Skendros P., Tselios K. et al. Study of immunomodulating effects of statins in rheumatoid arthritis patients with accelerated atherosclerosis. Ann. Rheum. Dis. 2008; 67(suppl. II): 205.
  31. Yokota K., Ishibashi T., Asanuma Y. et al. Simvastatin inhibits production of pentraxin 3 and monocyte chemoattractant protein-1 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67 (suppl. II): 207.
  32. Nah S., Won H., Shin B. et al. HMG-KoA reductase inhibitors (statins) inhibits the expansion of CD4+CD2S+ regulatory T cell. Ann. Rheum. Dis. 2008; 67 (suppl. II): 454.
  33. Lazzerini P. E., Lorenzini S., Selvi E. et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1b-stimulated synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 2007; 25: 696-700.
  34. Pucetti L., Pascui A. L., Auteri A. et al. Mechanisms for antiplatelet action of statins. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004; 5: 121-126.
  35. Yokota K., Mioyoshi F., Myazaki K. et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 2008; 35: 193-200.
  36. Charles-Schoeman C., Banquerigo M. L., Hama S. et al. Treatment with an apolipoprotein A-l mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol. 2008; 127: 234-244.
  37. Funk L., Chen J., Downey K. et al. Bone protective effect of simvastatin in experimental arthritis. J. Rheumatol. 2008; 35: 1083-1091.
  38. McCarey D. W., McInnes I. B., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004; 363: 2015-2021.
  39. Brugaletta S., Biasucci L. M., Pinnelli M. et al. Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart 2006; 92: 249-250.
  40. Okamoto H., Koizumi K., Kamitsuji S. et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 2007; 34: 964-968.
  41. Charles-Schoeman C., Khanna D., Furst D. E. et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A Pilot Study. J. Rheumatol. 2007; 34(7): 1458-1464.
  42. Hermann F., Forster A., Chenevard R. et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol. 2005; 45: 461-464.
  43. Tikiz C., Utuk O., Pirildar T. et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J. Rheumatol. 2005; 32: 2095-2101.
  44. Van Doornum S., McColl G., Wicks I. P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 1571-1575.
  45. Kumar P., Khan F., Kennedy G. et al. Effect of rosuvastatin on surrogate markers of cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67(suppl. II): 172.
  46. Millionis H. J., Liberopoulos E. N., Achimastos G. Statins: another class of antihypertensive agents? J. Hum. Hypertens. 2006; 20: 320-335.
  47. Mдki-Petдjд K. M., Booth A. D., Hall F. C. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Col1. Cardiol. 2007; 50(9): 852-858.
  48. Dixon W. G., Watson K. D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor-alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr. and Rheum. 2007; 56: 2905-2912.
  49. Jacobsson L. T., Askling J., Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann. Rheum. Dis 2008; 67(suppl. II): 183.
  50. Choi H. K., Hernan M. A., Seeger J. D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
  51. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthr. and Rheum. 2006; 55: 531-536.
  52. Jacobsson L. T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 2005; 32: 1213-1218
  53. Van Halm V. P., Nurmohamed M. T., Twisk J. W. et al. Antirheumatic drugs are associated with reduction of cardiovascular risk in patients with rheumatoid arthritis. Arthr. and Rheum. 2005; 52: S704.
  54. Solomon D. H., Avorn J., Katz J. N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthr. and Rheum. 2006; 54: 3790-3798.
  55. Georgiadis A. N., Papavasiliou E. C., Lourida E. S. et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthr. Res. Ther. 2006: 8: R82.
  56. Dixon W. G., Symmons D. P. What effects might anti-TNFa treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFa in cardiovascular pathophysiology. Ann. Rheum. Dis. 2007; 66: 1132-1136.
  57. Rachapalli S. M., Ravindran V., Malaiya R. et al. A systematic review of the effects of anti-TNF agents on lipid profile. Ann. Rheum. Dis. 2008; 67(suppl. II): 329.
  58. Triantafullou A. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with active inflammatory disease. Ann. Rheum. Dis. 2008; 67(suppl. II): 333.
  59. Nishida K., Okada Y., Nawata M. et al. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr. J. 2008; 55: 213-216.
  60. Dominguez H., Storgaard H., Rask-Madsen C. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 2005; 42: 517-525.
  61. Kiortsis D. N., Mavridis A. K., Vasakos S. et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 2005; 64: 765-766.
  62. Gonzales-Gay M. A., De Matias J. M., Gonzales-Juataney C. et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006; 24: 83-86.
  63. Huvers F. C., Popa C., Netea M. et al. Improved insulin sensitivity by anti-TNFa antibody treatment in patients with rheumatic diseases. Ann. Rheum. Dis. 2007; 66: 558-559.
  64. Hurlimann D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187.
  65. Gonzalez-Juanatey C., Testa A,, Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-alpha antibody. Arthr. and Rheum. 2004; 51: 447-450.
  66. Van Doornum S., McColl G., Wicks I. P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005; 44: 1428-1432.
  67. Angel K., Provan S. A., Agewall S. et al. TNF-alpha antagonists reduce arterial stiffness in patients with rheumatoid arthritis and related arthropaties: a controlled study. Ann. Rheum. Dis. 2008; 67(suppl. II): 160.
  68. Cypiene A., Laucevicius A., Venalis A. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc. West Pharmacol. Soc. 2007; 50: 119-122.
  69. Maki-Petaja K. M., Hall F. C., Booth A. D. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114: 1185-1192.
  70. Gonzales-Juataney C., Llorca J., Garcia-Porrua C. et al. Effect of anti-tumor necrosis factor-alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthr. and Rheum. 2006; 55: 150-153.
  71. Del Porto F., Lagana B., Lai S. et al. Response to anti-tumor necrosis factor-alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007; 46: 1111-1115.
  72. Mann D. L., McMurray J. J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results ot the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.
  73. Chung E. S., Packer M., Lo K. H. et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140.
  74. Danila M. I., Patkara N. M., Curtisa J. R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr. Opin. Rheum. 2008; 20: 327-333.
  75. Kwon H. J. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 2003; 138: 807-811.
  76. Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthr. and Rheum. 2006; 54: 2807-2816.
  77. Westhovens R., Yocum D., Han J. et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trlal. Arthr. and Rheum 2006; 54: 1075-1086.
  78. St Clair E. W., van der Heijde D. M., Smolen J. S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr. and Rheum. 2004; 50: 3432-3443.
  79. Schiff M. H., Burmester G. R., Kent J. D. et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006; 65: 889-894.
  80. Feltelius N., Fored C. M., Blomqvist P. et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann. Rheum. Dis. 2005; 64: 246-252.
  81. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 2004; 116: 305-311.
  82. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 2005; 44: 677-680.
  83. Curtis J. R., Kramer J. M., Martin C. et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology 2007; 46: 1688-1693.
  84. Carmona L., Descalzo M. A., Perez-Pampin E. AII-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann. Rheum. Dis. 2007; 66: 880-885.
  85. Listing J., Strangfeld A., Kekow J. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 2008; 58: 667-677.
  86. Wei L., MacDonald T. M., Walker B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 2004; 141: 764-770.
  87. Del Rincon I., O'Leary D. H., Haas R. W. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthr. and Rheum. 2004; 50: 3813-3822.
  88. Panoulas V. F., Metsios G. S., Pace A. V. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007; 46(9): 1477-1482.
  89. Gonzales-Gay M. Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic disease: myth or reality? Arthr. and Rheum. 2007; 57: 191-192.
  90. Davis J. M., Kremers M. H., Crowson C. S. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthr. and Rheum. 2007; 56: 820-830.
  91. Hafstrom I., Rohani M., Deneberg S. et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J. Rheumatol. 2007; 34: 1810-1816.

Statistics

Views

Abstract: 147

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Novikova D.S., Popkova T.V., Nasonov E.L., Novikova D.S., Popkova T.V., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies